🇺🇸

US SEC Filing Intelligence

Daily AI-powered analysis of SEC EDGAR filings, FDA approvals, and US regulatory disclosures. Investment signals, risk flags, and sector themes for US markets.

· daily

VA Healthcare & Services Contracts — October 31, 2026

This digest covers a single Department of Veterans Affairs award: an $88,992,131 firm-fixed-price delivery order to Medline Industries, LP (Northfield, IL) for September 2026 medical-surgical prime vendor expenditures, awarded under full and open competition with no set-aside. The stream is 100% civilian (0/1 defense-related), so there is no DOD, NDAA, or continuing-resolution exposure to weigh; the relevant budget context is VA medical-supply appropriation continuity. The highest-conviction read is that this is a recurring monthly prime vendor spend report rather than a new multi-year program — total obligation equals base-plus-options at $88,992,131, the performance period is a single month (2026-09-01 to 2026-09-30), and outlays to date are $0. Signal strength is 4/10 and materiality 4/10, neutral: meaningful absolute dollars but no incremental option value and no confirmed annualization. Key risk/watch item: the award-date (2026-10-28) versus start-date (2026-09-01) inconsistency and the absence of prior-month comparators mean the implied ~$1.07B annualized run-rate is unverified and should not be capitalized without recurrence data.

1 total filings
· daily

New Federal Contractors — October 31, 2026

The single award in this stream is an $88,992,131 firm-fixed-price delivery order to Medline Industries, LP from the Department of Veterans Affairs (SAC Frederick) for September 2026 medical-surgical prime vendor expenditures, making the period 100% civilian (0/1 defense-related) and dominated by VA medical-supply procurement. The signal is neutral (4/10 strength, 4/10 materiality): the dollar value is meaningful, but the performance period is a single month (2026-09-01 to 2026-09-30), total obligation equals base-plus-options at $88,992,131 with zero option value, and $0 has been outlayed to date, indicating a recurring monthly spend report rather than a new multi-year program. The award was full and open competition with no set-aside, and Medline is explicitly designated 'Not a Small Business,' reinforcing an entrenched large-supplier relationship with the VA. Highest-conviction takeaway is the scale of VA medical-surgical distribution spend (~$89M in one month, implying a ~$1.07B annualized run-rate only if the pattern repeats, which the data does not confirm). Key watch item is whether comparable monthly Medline VA prime vendor awards recur, plus resolution of the award-date (2026-10-28) versus start-date (2026-09-01) inconsistency and progression of outlays from $0.

1 total filings
· daily

Significant Contract Modifications ($10M+) — October 31, 2026

This digest covers a single significant contract modification: an $88,992,131 firm-fixed-price delivery order to Medline Industries, LP from the Department of Veterans Affairs (SAC Frederick) for medical-surgical prime vendor expenditures. The award is 100% civilian (0 defense-related contracts), making the VA medical-supply channel the sole theme this period. The highest-conviction signal is neutral: the obligation is meaningful in absolute dollars but represents only a one-month performance period (2026-09-01 to 2026-09-30) with $0 outlayed to date and base-plus-options identical to the base value, indicating a recurring monthly prime vendor spend report rather than a new multi-year program. Full and open competition with no set-aside and a non-small-business recipient signals an entrenched large-supplier relationship, but no incremental option value is created. Key watch items are whether similar monthly Medline VA awards recur (which would validate a ~$1.07B annualized run-rate that the data does NOT confirm) and the award-date (2026-10-28) versus start-date (2026-09-01) inconsistency.

1 total filings
· daily

Contract Deobligations Alert — October 31, 2026

This digest covers a single contract: an $88,992,131 firm-fixed-price delivery order to Medline Industries, LP from the Department of Veterans Affairs (SAC Frederick) for medical-surgical prime vendor expenditures for September 2026. The award is 100% civilian (VA), with zero defense-related obligations, and represents a recurring monthly spend report rather than a new multi-year program, as evidenced by a one-month performance period (2026-09-01 to 2026-09-30) and $0 outlayed to date. The highest-conviction signal is neutral: the dollar value is meaningful but short duration and no option value limit incremental revenue visibility. Key watch items include whether similar monthly VA prime vendor awards recur for Medline (to validate an annualized run-rate of ~$1.07B, which is not confirmed) and resolution of the award-date (2026-10-28) versus start-date (2026-09-01) inconsistency. Overall, this is a low-risk, low-signal data point that underscores Medline's established VA supply relationship but offers limited actionable investment intelligence on its own.

1 total filings
· daily

Contract Option Exercises — October 31, 2026

The sole contract in this digest is an $88.99M firm-fixed-price delivery order to Medline Industries, LP from the Department of Veterans Affairs (VA) for medical-surgical prime vendor expenditures for September 2026. This is a civilian agency award, with 0 defense-related contracts, and represents a recurring monthly spend report rather than a new multi-year program, as the performance period is only one month and total obligation equals base-plus-options. The signal is neutral (strength 4/10, materiality 4/10) due to the short duration and lack of incremental option value, despite the meaningful dollar amount. The highest-conviction takeaway is that Medline remains an established large supplier to the VA under full and open competition with no set-aside, but the single data point does not confirm an annualized run-rate. Key risk is the inconsistency between the award date (2026-10-28) and the start date (2026-09-01), and the $0 outlay to date, which warrants monitoring for recurrence and actual spending progression.

1 total filings
· daily

High-Value Federal Grants ($5M+) — October 31, 2026

This period contains a single high-value federal award: an $88,992,131 firm-fixed-price delivery order to Medline Industries, LP from the Department of Veterans Affairs (SAC Frederick) for medical-surgical prime vendor expenditures for September 2026. The award is 100% civilian (0/1 defense-related), with no DOD exposure, so it carries no direct defense-sector or NDAA-alignment signal. The dominant theme is VA medical-surgical supply distribution, and the highest-conviction takeaway is that Medline holds an established, full-and-open, non-set-aside prime vendor relationship with the VA — a modest positive for its government channel but not a new program win. The critical caveat is duration: the performance period is a single month (2026-09-01 to 2026-09-30), total obligation equals base-plus-options at $88,992,131 with no option value, and $0 has been outlayed to date, indicating a recurring monthly spend report rather than a multi-year commitment. Key watch items are whether similar monthly VA prime vendor awards recur (which would validate an annualized run-rate of roughly $1.07B) and the award-date (2026-10-28) versus start-date (2026-09-01) inconsistency.

1 total filings
· daily

General Federal Contracts — October 31, 2026

This period contains a single federal contract action: an $88,992,131 firm-fixed-price delivery order to Medline Industries, LP from the Department of Veterans Affairs (SAC Frederick) covering September 2026 medical-surgical prime vendor expenditures. The split is 100% civilian ($88.99M) and 0% defense, with no DOD exposure and therefore no direct NDAA or defense-budget linkage. The dominant theme is recurring VA medical-surgical supply distribution through a full-and-open, no-set-aside prime vendor arrangement with an established large supplier. The highest-conviction read is neutral: the dollar value is material, but the performance period is a single month (2026-09-01 to 2026-09-30), base and base-plus-options are identical at $88,992,131 (zero option value), and $0 has been outlayed to date, indicating a monthly spend report rather than a new multi-year program. Key watch items are whether similar monthly VA prime vendor awards recur (which would validate a ~$1.07B annualized run-rate that the data does NOT confirm) and the award-date (2026-10-28) versus start-date (2026-09-01) inconsistency.

1 total filings
· daily

Biotech Small-Cap Approvals — October 30, 2026

This period's digest covers 4 FDA approvals, all classified as 'Other' (FALLBACK) with no NMEs, biosimilars, or label expansions, and all carrying neutral signals. The approvals are for rivaroxaban (Teva), tranexamic acid (Zydus), propranolol HCl (Senores), and epinephrine (Gland), each with limited disclosed commercial data. No dominant therapeutic area theme emerges, as the drugs span anticoagulation, antifibrinolysis, cardiovascular, and emergency care. The highest-conviction signal is neutral across the board, with no differentiated upside or downside identified. Key risk is the lack of disclosed peak sales, exclusivity, or pricing power, which limits investment actionability.

4 total filings
· daily

New Drug Approvals (Original) — October 30, 2026

The October 30, 2026 FDA digest contains 4 approvals, all classified as 'Other' (FALLBACK) with 0 NMEs, 0 biosimilars, and 0 label expansions, yielding 4 neutral signals and no bullish or bearish catalysts. The four entries — rivaroxaban (Teva Pharms USA), tranexamic acid (Zydus Lifesciences), propranolol hydrochloride (Senores Pharms), and epinephrine (Gland) — are generic/duplicate-type filings rather than true biosimilars, despite the stream's biosimilar labeling, so originator erosion implications are limited and commercial data (peak sales, exclusivity, pricing power, market position) is NOT_DISCLOSED across all four. No therapeutic-area clustering of strategic significance emerges: the assets span anticoagulation, antifibrinolytic/hemostasis, cardiovascular beta-blockade, and emergency anaphylaxis, with no single TA gaining multiple high-value approvals. Highest-conviction signal is absent this period — no NME, no Breakthrough, Priority Review, Orphan, or Accelerated Approval designations were reported, so there is no differentiated commercial catalyst. Key watch item is whether these fallback generic entries signal early price erosion in the rivaroxaban (Xarelto) and epinephrine (EpiPen) classes, and whether any sponsor converts this cadence into higher-value pipeline events.

4 total filings
· daily

Federal Construction & Infrastructure Contracts — October 30, 2026

This digest covers a single federal construction award: a $69,535,671 firm-fixed-price definitive contract to Perini Management Services, Inc. (a Tutor Perini Corp subsidiary), awarded by the National Park Service under the Department of the Interior for rehabilitation of the Furnace Creek and Cow Creek water and wastewater treatment systems in Death Valley, CA. The award is 100% civilian (0/1 defense-related), so it carries no direct DOD or NDAA-driven signal and instead reflects Interior/NPS facility-infrastructure spending. The contract was full and open competition with no set-aside and the recipient is not a small business, indicating a merit-based win by an established contractor; the entire $69.5M is committed with no additional option ceiling disclosed. The highest-conviction signal is the backlog addition for Tutor Perini (~$21-23M/year across the ~32.4-month performance period from July 2026 to March 2029), though with $0 outlayed to date and a future award/start date this is forward-looking backlog rather than immediate revenue. Key watch items are confirmation of award finalization and cost performance under the firm-fixed-price structure, which shifts overrun risk to Perini.

1 total filings
· daily

Defense Manufacturing Contracts — October 30, 2026

This digest covers a single Department of Homeland Security contract modification awarded to Sierra Nevada Company, LLC, valued at $70,401,585, with a date listed as 2023-09-28. The award is entirely civilian (0 of 1 defense-related), so it does not signal DOD procurement trends. The signal is neutral (5/10 strength, 5/10 materiality) due to unknown pricing structure, competition status, and revenue contribution. The highest-conviction takeaway is limited: Sierra Nevada remains a DHS counterparty, but the lack of detail on scope, competition, and contract type prevents a directional investment call. Key watch items include potential re-compete or option exercise dates and any follow-on DHS awards that could clarify Sierra Nevada's civilian franchise.

1 total filings
· daily

DHS Homeland Security Contracts — October 30, 2026

This digest covers a single Department of Homeland Security contract modification to Sierra Nevada Company, LLC valued at $70,401,585, dated 2023-09-28, with 0 of 1 contracts classified as defense-related, making this a purely civilian-agency signal. The award is a modification rather than a new competitive win, and the source analysis flags pricing structure, competition basis, and revenue contribution as unknown, yielding a neutral signal strength of 5/10 and materiality of 5/10. The dominant theme is DHS sustainment/modification spending concentrated in a single recipient, which offers limited breadth for sector-level inference. Highest-conviction read: Sierra Nevada remains an incumbent of record at DHS, but the absence of disclosed competition, pricing, and program detail caps conviction. Key watch item: the underlying program office, option/re-compete timeline, and whether this modification is funded under a continuing resolution, since October-adjacent DHS obligations carry CR and budget-cycle exposure.

1 total filings
· daily

VA Healthcare & Services Contracts — October 30, 2026

This digest covers a single Department of Veterans Affairs (VA) contract awarded to Signature Choice III, LLC, a Service-Disabled Veteran-Owned Small Business (SDVOSB), with a total obligation of $226,106,338 and a base-plus-options ceiling of $418,223,061 for VA Claims and Customer Services. The award is entirely civilian (0 defense-related), firm-fixed-price, and was not competed, despite the recipient's SDVOSB status, raising questions about the application of set-aside rules. The highest-conviction signal is the sheer size of the obligation relative to the recipient's likely size, indicating a significant outsourcing opportunity in VA claims processing, but the neutral signal strength (4/10) and $0 outlayed temper immediate enthusiasm. Key risks include the lack of competition, potential protest, and execution risk under a firm-fixed-price delivery order. Investors should watch for outlay movement, option exercises toward the $418.2M ceiling, and any re-competition activity.

1 total filings
· daily

New Federal Contractors — October 30, 2026

The 8 contracts total $741.2M in obligations, with 0% defense-related and 100% civilian, dominated by HHS/CMS Medicare quality and consulting awards (4 contracts, $308.5M) and a large VA claims processing award ($226.1M). The highest-conviction signal is Tutor Perini's $69.5M firm-fixed-price National Park Service water infrastructure contract, the only bullish-rated award, though it carries execution risk. A key risk is the $226.1M VA award to Signature Choice III, which was not competed and has $0 outlayed, raising protest and funding uncertainty. Overall, the stream shows stable civilian services demand but limited direct public-equity exposure, as most recipients are private LLCs, nonprofits, or have anomalous data (SAIC subawards exceed prime value).

8 total filings
· daily

Significant Contract Modifications ($10M+) — October 30, 2026

This digest covers 8 contract modifications totaling $741.2M, all civilian with zero defense exposure. The dominant theme is CMS/Medicare advisory services, with four cost-plus-fixed-fee awards to private nonprofits (HSAG, TMF, Health Quality Innovators, Telligen) totaling $308.5M, but only ~$49.7M outlayed to date. The highest-conviction public-equity signal is Tutor Perini's $69.5M firm-fixed-price National Park Service water infrastructure award, a competitively won backlog item. Key risks include the unexercised option value across CMS contracts, anomalous subaward data on SAIC's $66.6M GSA delivery order, and the not-competed $226.1M VA award to Signature Choice III. Investors should watch option exercises and outlay progression as near-term catalysts.

8 total filings
· daily

Contract Deobligations Alert — October 30, 2026

This deobligations alert covers 8 contracts totaling $741.2M, all civilian-agency awards with zero defense exposure. The dominant theme is CMS/HHS Medicare quality and management consulting, with four cost-plus-fixed-fee delivery orders to private nonprofits and advisory firms (HSAG, TMF, Health Quality Innovators, Telligen) totaling $308.5M, but only $49.7M outlayed to date. The highest-conviction investable signal is Tutor Perini's $69.5M firm-fixed-price National Park Service water infrastructure award, though it is a forward-looking backlog item with $0 outlayed. The largest single obligation is a $226.1M non-competed VA claims services delivery order to Signature Choice III, a private SDVOSB with no public equity exposure. Key risk: most awards are multi-year with minimal outlays, and the SAIC contract shows anomalous subaward and negative outlay data that limit revenue attribution confidence.

8 total filings
· daily

Contract Option Exercises — October 30, 2026

This digest covers 8 contract option exercises totaling $741.2M, all civilian with zero defense-related awards. The dominant theme is CMS/HHS Medicare advisory services, with four cost-plus-fixed-fee delivery orders (HSAG $80.6M, TMF $77.5M, Health Quality Innovators $76.7M, Telligen $73.7M) awarded in 2025 under full and open competition, signaling stable but low-margin demand for external quality improvement contractors. The highest-conviction actionable signal is Tutor Perini's $69.5M firm-fixed-price National Park Service water infrastructure award, a forward-looking backlog item with execution risk. The largest obligation, $226.1M to Signature Choice III (VA), is a non-competed, SDVOSB-awarded claims processing order with $0 outlayed, limiting near-term visibility. Key risk: most contracts have significant unoutlayed balances (e.g., 81.5% for HSAG, 100% for Perini) and option exercises remain contingent on future appropriations.

8 total filings
· daily

Federal Professional Services Contracts — October 30, 2026

On October 30, 2026, four civilian professional services contracts totaling $308.5 million were awarded, all to non-public entities (three nonprofits and one woman-owned business) by the Department of Health and Human Services (HHS), specifically the Centers for Medicare and Medicaid Services (CMS). The awards are cost-plus-fixed-fee delivery orders for Medicare-related management consulting, with five-year performance periods through 2030 and only 12-18% of total value outlayed to date. The dominant theme is CMS's continued reliance on external quality improvement and advisory services, with no defense-related contracts in the stream. The highest-conviction signal is the $80.6 million award to Health Services Advisory Group, which, despite being the largest, has limited direct public equity impact due to the recipient's private status. Key watch items include the pace of incremental funding obligations and option exercises, as well as potential CMS budget pressures under a continuing resolution.

4 total filings
· daily

Federal IT & Cybersecurity Contracts — October 30, 2026

The single contract in this stream is a $66,618,385 GSA Federal Acquisition Service delivery order to Science Applications International Corporation (SAIC) for ClearPath Mainframe Hosting Services, awarded March 29, 2022 and running through December 2026 with a base-plus-options ceiling of $72,847,675. The award is entirely civilian (0/1 defense-related), full and open competition with no set-aside, and firm fixed price under NAICS 541512 / PSC DA10, placing it in legacy mainframe hosting and application development rather than defense hardware. The highest-conviction signal is modest: roughly $6.2M of option headroom remains before the December 31, 2026 expiration, implying approximately $14.2M-$15.5M of annual revenue recognition if obligations are spread evenly across the ~4.75-year period. The dominant risk is data quality: 53 subawards totaling $126,366,678 exceed the prime obligation, and total outlayed is reported as negative ($-65,728), which materially limits confidence in net revenue attribution to SAIC. With a neutral 5/10 signal strength and 3/10 materiality, this is a low-impact data point for SAIC's overall revenue base and not a standalone thesis driver.

1 total filings
· daily

All HHS Contracts — October 30, 2026

This digest covers four HHS/CMS contracts totaling $308.5M, all awarded to private entities (three nonprofits and one woman-owned business) for Medicare quality and management consulting services under NAICS 541618/PSC Q101. The awards are 100% civilian, with zero defense-related obligations, reflecting CMS's continued investment in external advisory support through cost-plus-fixed-fee delivery orders. The highest-conviction signal is the concentration of four similar awards to non-public entities, limiting direct public-equity read-through but signaling stable demand for CMS consulting services. A key risk is that only ~13% of total value has been outlayed to date, leaving ~$268M contingent on option exercises and future funding. Investors should watch for public contractors like Leidos, Booz Allen Hamilton, and Maximus that may compete for similar CMS work, though these specific awards offer no direct equity catalyst.

4 total filings